CNDAC (DFP-10917; TAS-109) is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity.

Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It

Citarinostat(ACY-241) is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.

Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

CID-797718 is a compound with unknown details.

CID-2011756 is a cell-active ATP competitive and specific PKD1 inhibitor that inhibits phorbol ester-induced endogenous PKD1 activation in LNCaP prostate cancer cells.

CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.

CGP 71683A is a potent and highly selective non-peptide antagonist of the NPY Y(5) receptor in the study of obesity.

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.

Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

CDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM.

CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.

CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR).

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.

CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.

CCF642 is a novel protein disulfide isomerases (PDI) inhibitor.

CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8).

CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase.

CAY10585 prevented HIF-1 transcriptional activity with IC50 values of 2.6 and 0.7 µM, respectively.

CASIN is a Cdc42 GTPase inhibitor (IC50 = 2 μM).

Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent.

Cardamonin, isolated from the fruits of Alpinia species, is a chalconoid with anti-inflammatory and anti-tumor activity.

Capromorelin tartrate is a potent ghrelin receptor agonist/growth hormone secretagogue (Ki = 7 nM).

Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

Cangrelor (AR-C69931MX) is a potent, selective P2T/P2Y12 receptor antagonist with IC50 of 0.4 nM against ADP-induced aggregation of human platelets.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.

BX517 is a novel phosphoinositide-dependent kinase-1 (PDK1) inhibitor.